JP7164798B2 - Ｔ細胞前駆体を産生させるための方法 - Google Patents

Ｔ細胞前駆体を産生させるための方法 Download PDF

Info

Publication number
JP7164798B2
JP7164798B2 JP2019565052A JP2019565052A JP7164798B2 JP 7164798 B2 JP7164798 B2 JP 7164798B2 JP 2019565052 A JP2019565052 A JP 2019565052A JP 2019565052 A JP2019565052 A JP 2019565052A JP 7164798 B2 JP7164798 B2 JP 7164798B2
Authority
JP
Japan
Prior art keywords
cells
cell
tnf
cell precursors
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513844A5 (enExample
JP2020513844A (ja
Inventor
アンドレ，イザベル
カヴァッザーナ，マリナ
マ，クーイン
チェン，ジョン
ソヘイリ，タイベ－シャビ
モイランテム，ランジタ デビ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Cite
Original Assignee
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Cite filed Critical Universite Paris Cite
Publication of JP2020513844A publication Critical patent/JP2020513844A/ja
Publication of JP2020513844A5 publication Critical patent/JP2020513844A5/ja
Priority to JP2022154550A priority Critical patent/JP2022185024A/ja
Application granted granted Critical
Publication of JP7164798B2 publication Critical patent/JP7164798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2019565052A 2017-02-13 2018-02-12 Ｔ細胞前駆体を産生させるための方法 Active JP7164798B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022154550A JP2022185024A (ja) 2017-02-13 2022-09-28 Ｔ細胞前駆体を産生させるための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305161.6 2017-02-13
EP17305161 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022154550A Division JP2022185024A (ja) 2017-02-13 2022-09-28 Ｔ細胞前駆体を産生させるための方法

Publications (3)

Publication Number Publication Date
JP2020513844A JP2020513844A (ja) 2020-05-21
JP2020513844A5 JP2020513844A5 (enExample) 2021-03-25
JP7164798B2 true JP7164798B2 (ja) 2022-11-02

Family

ID=58185453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019565052A Active JP7164798B2 (ja) 2017-02-13 2018-02-12 Ｔ細胞前駆体を産生させるための方法
JP2022154550A Pending JP2022185024A (ja) 2017-02-13 2022-09-28 Ｔ細胞前駆体を産生させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022154550A Pending JP2022185024A (ja) 2017-02-13 2022-09-28 Ｔ細胞前駆体を産生させるための方法

Country Status (17)

Country Link
US (5) US20200046767A1 (enExample)
EP (2) EP3580330B1 (enExample)
JP (2) JP7164798B2 (enExample)
KR (1) KR102666158B1 (enExample)
CN (1) CN110506110B (enExample)
AU (1) AU2018217404B2 (enExample)
BR (1) BR112019016672A8 (enExample)
CA (1) CA3053294A1 (enExample)
DK (1) DK3580330T3 (enExample)
ES (1) ES2931530T3 (enExample)
HU (1) HUE060548T2 (enExample)
IL (1) IL268641B2 (enExample)
MA (1) MA47541A (enExample)
PL (1) PL3580330T3 (enExample)
PT (1) PT3580330T (enExample)
WO (1) WO2018146297A1 (enExample)
ZA (1) ZA201905470B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268641B2 (en) * 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors
US20200308540A1 (en) * 2017-09-29 2020-10-01 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
CN112041431A (zh) 2018-02-14 2020-12-04 桑尼布鲁克研究所 产生t细胞谱系细胞的方法
CA3109546A1 (en) * 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
US20220315895A1 (en) * 2019-05-01 2022-10-06 Transfusion Health, Llc Methods of making oligopotent and unipotent precursors
CA3144640A1 (en) * 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
CA3159629A1 (en) * 2019-11-14 2021-05-20 Peter William ZANDSTRA Media formulations and methods for producing progenitor t cells
US20230159891A1 (en) * 2020-03-31 2023-05-25 Kyoto University T cell progenitor production method
JP2023553313A (ja) 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体
CA3213581A1 (en) * 2021-05-25 2022-12-01 Kai Ling LIANG Generating t cell precursors via agonizing tumor necrosis factor receptor 2
EP4426319A1 (en) 2021-11-04 2024-09-11 APHP (Assistance Publique - Hôpitaux de Paris) Method for generating nk cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
AU2024211048A1 (en) 2023-01-27 2025-08-07 Notch Therapeutics (Canada), Inc. Method for generating t cell lineage populations from stem/progenitor cells
WO2024175738A1 (en) * 2023-02-22 2024-08-29 Smart Immune Method for thymus regeneration
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508188A (ja) 2008-11-07 2012-04-05 サニーブルック ヘルス サイエンシズ センター ヒト前駆ｔ細胞
US20140369973A1 (en) 2011-12-08 2014-12-18 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2016055396A1 (fr) 2014-10-06 2016-04-14 Assistance Publique - Hopitaux De Paris Méthode de génération de progéniteurs de cellules t
JP2016526913A (ja) 2013-08-02 2016-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
WO2016205680A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
RU2535966C2 (ru) 2008-09-12 2014-12-20 Криопрашис Криобиоложия Лтда. Клеточная терапия ишемической ткани
WO2011068962A1 (en) 2009-12-03 2011-06-09 The University Of Utah Research Foundation Methods for generating t lymphocytes from hematopoietic stem cells
US20130095079A1 (en) 2010-04-09 2013-04-18 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2014110353A1 (en) 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Notch ligand bound bicompatible substrates and their use in bone formation
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
US10131876B2 (en) * 2014-04-24 2018-11-20 Miltenyi Biotec Gmbh Method for automated generation of genetically modified T cells
WO2016039933A1 (en) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
EP3440198A4 (en) 2016-04-08 2019-11-06 The Governing Council of the Universtiy of Toronto PROCESS FOR THE PRODUCTION OF PRE-TREATMENT T CELLS FROM TRUNK AND / OR PRECURSOR CELLS AND USE THEREOF
IL268641B2 (en) * 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508188A (ja) 2008-11-07 2012-04-05 サニーブルック ヘルス サイエンシズ センター ヒト前駆ｔ細胞
US20140369973A1 (en) 2011-12-08 2014-12-18 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
JP2016526913A (ja) 2013-08-02 2016-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
WO2016055396A1 (fr) 2014-10-06 2016-04-14 Assistance Publique - Hopitaux De Paris Méthode de génération de progéniteurs de cellules t
WO2016205680A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood, 2000, 95(9), pp.2806-2812
Stem Cells, 2012, 30(8), pp.1771-1780

Also Published As

Publication number Publication date
US11426430B2 (en) 2022-08-30
US20210169934A1 (en) 2021-06-10
HUE060548T2 (hu) 2023-03-28
US11638723B2 (en) 2023-05-02
ES2931530T3 (es) 2022-12-30
KR20190117550A (ko) 2019-10-16
JP2022185024A (ja) 2022-12-13
AU2018217404A1 (en) 2019-09-05
AU2018217404A2 (en) 2019-09-19
US20210169935A1 (en) 2021-06-10
MA47541A (fr) 2019-12-18
US20230293586A1 (en) 2023-09-21
CN110506110B (zh) 2024-09-06
IL268641B2 (en) 2024-10-01
KR102666158B1 (ko) 2024-05-16
IL268641A (en) 2019-10-31
RU2019125600A3 (enExample) 2021-11-03
CA3053294A1 (en) 2018-08-16
CN110506110A (zh) 2019-11-26
AU2018217404B2 (en) 2024-03-28
PT3580330T (pt) 2022-12-06
IL268641B1 (en) 2024-06-01
RU2019125600A (ru) 2021-03-15
US11642376B2 (en) 2023-05-09
JP2020513844A (ja) 2020-05-21
BR112019016672A2 (pt) 2020-04-14
PL3580330T3 (pl) 2023-01-16
EP3580330A1 (en) 2019-12-18
DK3580330T3 (da) 2022-12-05
ZA201905470B (en) 2024-12-18
BR112019016672A8 (pt) 2022-11-22
US20200046767A1 (en) 2020-02-13
EP4067482A1 (en) 2022-10-05
WO2018146297A1 (en) 2018-08-16
EP3580330B1 (en) 2022-08-31
US20200390817A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JP7164798B2 (ja) Ｔ細胞前駆体を産生させるための方法
US12071635B2 (en) Method for generating T-cell progenitors
KR100858857B1 (ko) 항원특이적 세포상해성 ｔ 세포 확대배양방법
JP2019170176A (ja) ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
WO2005054459A1 (ja) 造血幹細胞あるいは血管内皮前駆細胞の製造方法
RU2797260C2 (ru) Способ получения предшественников т-клеток
HK40081656A (en) Method for generating t cells progenitors
HK40017982A (en) Method for generating t cells progenitors
HK40017982B (en) Method for generating t cells progenitors
WO2025220666A1 (en) Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors
US20250361487A1 (en) Natural killer cell lineages derived from pluripotent cells
Shukla Controlled generation of progenitor T-Cells from hematopoietic stem cells and pluripotent stem cells
Mohtashami et al. Artificial Thymus: Recreating Microenvironmental Cues to Direct T Cell Differentiation and Thymic Regeneration
Guerrettaz Aging-associated changes in B-lymphopoiesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220916

R150 Certificate of patent or registration of utility model

Ref document number: 7164798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250